VBI Vaccines (VBIV) Granted FDA Approval of Investigational New Drug Application for Sci-B-Vac(R) Phase 3 Clinical Program

Go back to VBI Vaccines (VBIV) Granted FDA Approval of Investigational New Drug Application for Sci-B-Vac(R) Phase 3 Clinical Program
(NASDAQ: VBIV) Delayed: 0.92 +0.06 (6.98%)
Previous Close $0.86    52 Week High $4.35 
Open $0.89    52 Week Low $1.76 
Day High $0.92    P/E N/A 
Day Low $0.84    EPS $0.00 
Volume 1,759,080